Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.71 Consensus PT from Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have received an average recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $85.71.

Several research firms have commented on GPCR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Friday, May 3rd. Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, February 27th.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently made changes to their positions in the stock. FORA Capital LLC purchased a new position in Structure Therapeutics in the 1st quarter valued at approximately $732,000. China Universal Asset Management Co. Ltd. grew its holdings in Structure Therapeutics by 115.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,376 shares of the company’s stock valued at $402,000 after purchasing an additional 5,027 shares during the last quarter. TrueMark Investments LLC increased its position in shares of Structure Therapeutics by 13.5% in the first quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock valued at $1,281,000 after buying an additional 3,562 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after buying an additional 3,504,747 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Structure Therapeutics by 498.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 427,735 shares of the company’s stock worth $17,434,000 after buying an additional 356,302 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Trading Down 0.3 %

GPCR stock opened at $39.22 on Friday. The business has a 50 day simple moving average of $39.15 and a 200-day simple moving average of $46.25. The company has a market capitalization of $1.83 billion and a P/E ratio of -47.25. Structure Therapeutics has a twelve month low of $21.79 and a twelve month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Friday, March 8th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. Research analysts predict that Structure Therapeutics will post -0.98 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.